CV Sciences: What Went Wrong

About: CV Sciences, Inc. (CVSI)
by: Winds Research
This article is exclusive for subscribers.
Winds Research
Long/short equity, growth at reasonable price, long-term horizon, small-cap

CV Sciences has spent the last 12 months in free fall.

The company's Q3 2019 earnings results confirmed many fears selling shareholders would have had.

The pharmaceuticals division is a dud and needs to be divested.

Less than one year ago CV Sciences (OTCQB:CVSI) was trading at $6.25. The company, like Charlotte's Webb and Elixinol, the other companies in its space, were riding high on elevated valuations as investors